Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott W Lowe

Showing results (111-120 of 321) with videos related to

Pageof 33
Sort By:
Nature Protocols|February 4, 2012
A pipeline for the generation of shRNA transgenic miceLukas E Dow, Prem K Premsrirut, Johannes Zuber, et al.
Genes & Development|August 19, 2008
Tumorigenic activity and therapeutic inhibition of Rheb GTPaseKonstantinos J Mavrakis, Hong Zhu, Ricardo L A Silva, et al.
Nature|August 12, 2005
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutantsMichael T Hemann, Anka Bric, Julie Teruya-Feldstein, et al.
The Journal of Biological Chemistry|February 4, 2017
USP39 Deubiquitinase Is Essential for <i>KRAS</i> Oncogene-driven CancerJulia M Fraile, Eusebio Manchado, Amaia Lujambio, et al.
Cell|February 24, 2018
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage ResponseTakayuki Hoshii, Paolo Cifani, Zhaohui Feng, et al.
Genes & Development|December 17, 2009
miR-19 is a key oncogenic component of mir-17-92Virginie Olive, Margaux J Bennett, James C Walker, et al.
Nature Cell Biology|October 22, 2002
Direct coupling of the cell cycle and cell death machinery by E2FZaher Nahle, Julia Polakoff, Ramana V Davuluri, et al.
Genes & Development|September 26, 2013
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibitionChong Chen, Yu Liu, Chao Lu, et al.
Nature Cancer|February 5, 2022
A roadmap for the next decade in cancer researchRené Bernards, Elizabeth Jaffee, Johanna A Joyce, et al.
The Journal of Biological Chemistry|March 3, 2005
p400 is required for E1A to promote apoptosisAndrew V Samuelson, Masako Narita, Ho-Man Chan, et al.
Pageof 33

Showing results (111-120 of 321) with videos related to

Sort By:
Pageof 33
Nature Protocols|February 4, 2012
A pipeline for the generation of shRNA transgenic miceLukas E Dow, Prem K Premsrirut, Johannes Zuber, et al.
Genes & Development|August 19, 2008
Tumorigenic activity and therapeutic inhibition of Rheb GTPaseKonstantinos J Mavrakis, Hong Zhu, Ricardo L A Silva, et al.
Nature|August 12, 2005
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutantsMichael T Hemann, Anka Bric, Julie Teruya-Feldstein, et al.
The Journal of Biological Chemistry|February 4, 2017
USP39 Deubiquitinase Is Essential for <i>KRAS</i> Oncogene-driven CancerJulia M Fraile, Eusebio Manchado, Amaia Lujambio, et al.
Cell|February 24, 2018
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage ResponseTakayuki Hoshii, Paolo Cifani, Zhaohui Feng, et al.
Genes & Development|December 17, 2009
miR-19 is a key oncogenic component of mir-17-92Virginie Olive, Margaux J Bennett, James C Walker, et al.
Nature Cell Biology|October 22, 2002
Direct coupling of the cell cycle and cell death machinery by E2FZaher Nahle, Julia Polakoff, Ramana V Davuluri, et al.
Genes & Development|September 26, 2013
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibitionChong Chen, Yu Liu, Chao Lu, et al.
Nature Cancer|February 5, 2022
A roadmap for the next decade in cancer researchRené Bernards, Elizabeth Jaffee, Johanna A Joyce, et al.
The Journal of Biological Chemistry|March 3, 2005
p400 is required for E1A to promote apoptosisAndrew V Samuelson, Masako Narita, Ho-Man Chan, et al.
Pageof 33